OPTIMAL ORGANOPROTECTION, CONTROL OF bLOOD PRESSURE AND METAbOLIC DISORDER  WITH THE FIxED COMbINATION OF LISINOPRIL, AMLODIPINE AND ROSUVASTATIN IN SYSTEMIC  HYPERTENSION

Недогода, С. В.; Чумачек, Е. В.; Ledyaeva, A. A.; Tsoma, V. V.; Salasyuk, A. S.; Смирнова, В. О.; Hripaeva, Victoria Yu.; Палашкин, Р. В.; Попова, Е. А.

doi:10.15829/1560-4071-2018-4-49-55

Cited by 10 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Имевшиеся у включенных в исследование больных АГ и гиперхолестеринемия обосновали выбор лечащими врачами применения тройной ФК ЛАР с антигипертензивным и гиполипидемическим эффектами. Выявленное в процессе наблюдения снижение АД и ОХС по уровню было сопоставимо с ранее проведен- Efficacy of the Single Pill Combination in Treatment of Hypertensive Patients Эффективность фиксированной комбинации при артериальной гипертонией ными исследованиями [5][6][7][8][9][10][11][12]. В эти исследования всего было включено 3878 больных АГ с гиперлипидемией.…”

Section: Efficacy Of the Single Pill Combination In Treatment Of Hypertensive Patientsunclassified

“…Клинический опыт применения ФК ЛАР почти у 4 тыс больных с высоким сердечно-сосудистым риском, связанным с АГ и дислипидемией, показал высокую эффективность препарата в снижении систолического (САД) и диастолического (ДАД) АД, холестерина липопротеинов низкой плотности (соответственно на 25%, 17% и 40%), показателей сосудистой ригидности, маркеров фиброза и воспаления. Частота развития побочных эффектов при приеме ФК ЛАР в клинических исследованиях не превышала 5% [5][6][7][8][9][10].…”

Section: Introductionunclassified

See 1 more Smart Citation

Epidemiological Observational Study on the Assessment of the Comorbidity and the Efficacy of the Treatment of Hypertensive Patients with Single Pill Combination of Lysinopril, Amlodipine and Rosuvastatin "PHENOTYPE-AG"

Савенков

Иванов²,

Borschevskaya

et al. 2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To study the prevalence of comorbidity affecting the choice of antihypertensive treatment, as well as the efficacy and safety of the application of a single pill combination of lysinopril, amlodipine and rosuvastatin (SPC LAR) in hypertensive patients.Material and methods. Observational epidemiological study with the participation of 626 doctors and 13037 hypertensive patients with high cardiovascular risk and dyslipidemia treated with SPC LAR were held in 24 cities of Russia from November 2020 to March 2021. Prevalence and types of comorbidity, changes of blood pressure (BP), of total cholesterol (TC) and blood glucose levels and adverse events were studied during observation. Patients had 3 visits – initially, after 4 and 12 weeks. The obtained data was recorded by doctors through a web portal.Results. Concominant cardiovascular diseases found in all patients (in 38.7% of cases – from 2 to 5 diseases). The most commonly diseases were coronary artery disease (43.1%), metabolic syndrome (36.6%), diabetes (25.2%), chronic heart failure (24.9%), cerebrovascular diseases (12.3%) and chronic obstructive pulmonary disease (0.5%). SPC LAR with minimal doses of components (in 41.1% of patients) or with reinforced antihypertensive or hypocholesterolemic effects, based on the experience of treatment, the patient was prescribed as starting treatment with doctors. Reducing the level of systolic and diastolic BP, as well as the level Tc, respectively, by 20.9%, 16.9% and 29.7% found during the study. Target levels of systolic BP were achieved in 97.6% of patients, diastolic BP – in 99.6%, and target levels TC ≤5 mmol/l, ≤4 mmol/l and ≤3 mmol/l were achieved, respectively, in 94.5%, 68.6% and 23.5% patients. No significant dynamics of the level of glycemia were not found. The treatment was well tolerated by patients. Side effects found in 0.53% of patients (more often there was a dry cough, feet edema and headache). Commitment to treatment was 92.7%.Conclusion. The modern hypertension phenotype has cardiovascular atherosclerosis-associated diseases, which justifies the need to combine antihypertensive and hypolipidemic therapy. Triple SPC LAR, which effectively controlled the blood pressure and improved the violation of lipid metabolism was prescribed to patients in this observational study. The low frequency of side effects and good tolerance of treatment was accompanied by a high adherence of patients to treatment.

show abstract

Section: Efficacy Of the Single Pill Combination In Treatment Of Hypertensive Patientsunclassified

Section: Introductionunclassified

Epidemiological Observational Study on the Assessment of the Comorbidity and the Efficacy of the Treatment of Hypertensive Patients with Single Pill Combination of Lysinopril, Amlodipine and Rosuvastatin "PHENOTYPE-AG"

Савенков

Иванов²,

Borschevskaya

et al. 2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

Optimization of blood pressure control, organ protection and metabolic disorders using a fixed-dose combination of lisinopril+amlodipine+rosuvastatin in hypertensive patients after COVID-19

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aim. To evaluate the potential of a fixed-dose combination of lisinopril+amlodipine+rosuvastatin (Equamer®) in achieving additional vascular protection in patients with hypertension and high pulse wave velocity (PWV) after severe and very severe coronavirus disease 2019 (COVID-19), complicated by bilateral multisegmental viral pneumonia, with the use of biological therapy, who had not previously received combination antihypertensive therapy.Material and methods. This 12-week open-label observational study included 30 patients with or without antihypertensive therapy. The patients underwent 24-hour blood pressure monitoring, applanation tonometry (determination of the augmentation index (AI) and central blood pressure (CBP)), PWV measurement, blood laboratory tests (lipid profile, fasting glucose, C-reactive protein, complete blood count, ferritin, fibrinogen, D-dimer, alanine aminotransferase, aspartate aminotransferase, creatinine, uric acid) before and after switch to a fixed-dose combination of lisinopril+amlodipine+rosuvastatin.Results. At baseline, the patients had an increase in office blood pressure (BP) up to 152,6/89,1 mm Hg. After prescribing a fixed-dose combination of lisinopril+amlodipine+rosuvastatin, there was a decrease in systolic blood pressure (SBP) by 15,8% and diastolic blood pressure (DBP) by 12,2%. According to 24-hour blood pressure monitoring, the decrease in SBP was 15%, DBP — by 9%, PWV — by 23,8%, AI — by 9%, CBP — by 12,4% (p<0,05 for all compared to baseline values). Vascular age (VA) was initially increased to 41,9 years with a chronological age of 35,03 years. After the end of therapy, there was a significant decrease in VA to 36,5 years, low-density lipoproteins by 46,8%, triglycerides by 16,8% and an increase in high-density lipoproteins by 10,7% (p<0,05 for all compared to baseline values). In addition, the levels of C-reactive protein, fibrinogen, D-dimer, glucose, and uric acid significantly decreased.Conclusion. The fixed-dosed combination of lisinopril+amlodipine+rosuvastatin provides better blood pressure control, improved vascular elasticity parameters (AI, PWV, CBP, decrease in VA), and also improves lipid and carbohydrate metabolism, reduces inflammation in patients with hypertension and hyperlipidemia after severe COVID-19.

show abstract

Lipid metabolism disorders in patients with hypertension and diabetes mellitus: development and current treatment options

Podzolkov,

Tarzimanova,

Abramova

et al. 2023

Cardiovasc Ther Prev

View full text Add to dashboard Cite

The article presents the main mechanisms of development of lipid metabolism disorders and endothelial dysfunction in patients with hypertension (HTN) and type 2 diabetes (T2D), and their contribution to cardiovascular events. Modern approaches to the treatment of hypertension and dyslipidemia in people with type 2 diabetes are considered from the standpoint of the latest clinical guidelines, focusing on fixed-dose combinations as a means of an integrated approach to managing risk factors in comorbid patients. Data are presented on the efficacy and safety of fixed-dose combination of lisinopril, amlodipine and rosuvastatin in patients with hypertension and T2D.

show abstract

OPTIMAL ORGANOPROTECTION, CONTROL OF bLOOD PRESSURE AND METAbOLIC DISORDER WITH THE FIxED COMbINATION OF LISINOPRIL, AMLODIPINE AND ROSUVASTATIN IN SYSTEMIC HYPERTENSION

Cited by 10 publications

References 30 publications

Epidemiological Observational Study on the Assessment of the Comorbidity and the Efficacy of the Treatment of Hypertensive Patients with Single Pill Combination of Lysinopril, Amlodipine and Rosuvastatin "PHENOTYPE-AG"

Epidemiological Observational Study on the Assessment of the Comorbidity and the Efficacy of the Treatment of Hypertensive Patients with Single Pill Combination of Lysinopril, Amlodipine and Rosuvastatin "PHENOTYPE-AG"

Optimization of blood pressure control, organ protection and metabolic disorders using a fixed-dose combination of lisinopril+amlodipine+rosuvastatin in hypertensive patients after COVID-19

Lipid metabolism disorders in patients with hypertension and diabetes mellitus: development and current treatment options

Contact Info

Product

Resources

About